tru Independence LLC Cuts Stock Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

tru Independence LLC reduced its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 4.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 907 shares of the medical instruments supplier’s stock after selling 47 shares during the period. tru Independence LLC’s holdings in West Pharmaceutical Services were worth $299,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also bought and sold shares of WST. Caprock Group LLC boosted its position in shares of West Pharmaceutical Services by 6.6% during the 2nd quarter. Caprock Group LLC now owns 1,105 shares of the medical instruments supplier’s stock valued at $364,000 after acquiring an additional 68 shares during the last quarter. Acadian Asset Management LLC lifted its stake in West Pharmaceutical Services by 108.6% during the 2nd quarter. Acadian Asset Management LLC now owns 4,926 shares of the medical instruments supplier’s stock worth $1,620,000 after acquiring an additional 2,565 shares in the last quarter. SRS Capital Advisors Inc. lifted its holdings in West Pharmaceutical Services by 11.3% during the 2nd quarter. SRS Capital Advisors Inc. now owns 2,353 shares of the medical instruments supplier’s stock worth $775,000 after buying an additional 238 shares in the last quarter. Advisor OS LLC boosted its stake in shares of West Pharmaceutical Services by 7.9% in the 2nd quarter. Advisor OS LLC now owns 3,018 shares of the medical instruments supplier’s stock valued at $994,000 after buying an additional 221 shares during the period. Finally, Private Advisor Group LLC increased its holdings in West Pharmaceutical Services by 12.8% in the second quarter. Private Advisor Group LLC now owns 1,831 shares of the medical instruments supplier’s stock valued at $603,000 after buying an additional 208 shares during the last quarter. 93.90% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, SVP Silji Abraham sold 1,800 shares of the stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total transaction of $595,404.00. Following the completion of the sale, the senior vice president now directly owns 2,860 shares of the company’s stock, valued at $946,030.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, SVP Silji Abraham sold 1,800 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total value of $595,404.00. Following the completion of the sale, the senior vice president now owns 2,860 shares in the company, valued at $946,030.80. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Charles Witherspoon sold 1,029 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the transaction, the vice president now owns 1,478 shares in the company, valued at approximately $443,400. The disclosure for this sale can be found here. Corporate insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Stock Performance

Shares of WST opened at $297.24 on Friday. The stock has a 50 day moving average price of $307.36 and a 200 day moving average price of $341.24. West Pharmaceutical Services, Inc. has a 52-week low of $265.00 and a 52-week high of $413.70. The company has a quick ratio of 1.68, a current ratio of 2.34 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $21.65 billion, a price-to-earnings ratio of 39.21, a price-to-earnings-growth ratio of 10.84 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.22). West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The business had revenue of $702.10 million during the quarter, compared to analysts’ expectations of $729.36 million. During the same quarter last year, the company earned $2.11 EPS. The firm’s revenue for the quarter was down 6.9% compared to the same quarter last year. Research analysts predict that West Pharmaceutical Services, Inc. will post 6.44 EPS for the current fiscal year.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.